Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005

Executive Summary

FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005

You may also be interested in...



FDA Nominee Is Crawford: Choice Emphasizes Continuity, Cooperation

The Bush Administration's announcement that it intends to nominate Lester Crawford to be permanent FDA commissioner means that the pharmaceutical industry can count on continuity heading into the renewal process for the prescription drug user fee program

FDA Nominee Is Crawford: Choice Emphasizes Continuity, Cooperation

The Bush Administration's announcement that it intends to nominate Lester Crawford to be permanent FDA commissioner means that the pharmaceutical industry can count on continuity heading into the renewal process for the prescription drug user fee program

“Follow-On” Biologics Guidance Will Limit Use Of Data To “Public Domain”

FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5

Related Content

UsernamePublicRestriction

Register

PS043668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel